High Rate of Undetectable MRD with Venetoclax-Based Regimen in Untreated CLL

Time-limited treatment with bendamustine, rituximab, and venetoclax was associated with high rates of undetectable minimal residual disease (MRD) remission in a phase II study of adults with untreated chronic lymphocytic leukemia (CLL). These data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exhibition. At data cut-off, 26 patients were enrolled, … Continue reading High Rate of Undetectable MRD with Venetoclax-Based Regimen in Untreated CLL